SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or “bluebird”) today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data ...
A significantly greater percentage of patients treated with mitapivat achieved hemoglobin response compared with those who received placebo. Topline results were announced from a phase 3 trial ...
Compared with common care, gene therapy for sickle cell disease (SCD) would likely be cost-effective if its price was below $2 million, according to a comparative modeling analysis. At an assumed $2 ...
By Shreoshree Chakrabarty: Sickle Cell Disease (SCD) is a group of inherited blood disorders that affect the shape and function of red blood cells. The most severe form, Sickle Cell Anemia, occurs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results